GlassScriptPhysician profile
Matthew Jay Priddy
NPI 1265575708
$473.41
in general payments reported to CMS, 2019-2025
15 companies · $84.40 in 2025
The $84.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.55 · 2021: $23.44 · 2022: $85.62 · 2023: $173 · 2024: $61.18 · 2025: $84.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.26 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123.62 | 2021-2023 | Wegovy |
| Cleerly, INC. | $46.56 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Itamar Medical INC | $44.33 | 2025 | Watchpatone |
| Amgen INC. | $35.85 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $34.08 | 2022-2023 | Mounjaro |
| Terumo Medical Corporation | $32.96 | 2020 | |
| Aimmune Therapeutics, INC. | $28.20 | 2024 | |
| Glaxosmithkline, LLC. | $22.87 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $17.52 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 | |
| Abbott Laboratories | $15.40 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $14.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2023 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $13.24 | 2024 | Airsupra |
| Allergan, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Priddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.